Core Viewpoint - The 2026 investment outlook for the A-share market highlights the impact of geopolitical changes and technological innovations, particularly in AI, on capital markets, while addressing potential challenges and opportunities for investors [3][4][31]. Market Overview - The A-share market has shown a bullish trend, with major indices recording their second consecutive year of positive annual K-lines, particularly the Shanghai Composite Index reaching a 10-year high [4][32]. - Historical data indicates that the A-share market has never recorded three consecutive years of positive annual K-lines, raising questions about the potential for a new cycle in 2026 [4][33]. Key Drivers of the Bull Market - The bull market is driven by several core factors, including the government's strong emphasis on the stock market, a prolonged low-interest-rate environment favoring dividend stocks, and the stock market's emergence as a leading asset class with mid-term growth potential [5][34][36]. - The market's dynamics are influenced by both short-term and mid-term variables, with the potential emergence of new long-term cycle variables that may not be immediately recognized by investors [4][33]. Market Consensus and Analysis - The consensus among analysts is that the government is committed to high-quality capital market development, as evidenced by various supportive policies introduced since early 2024 [5][34]. - The low-interest-rate environment has been beneficial for dividend-paying stocks, which have become a core component of long-term investment strategies [5][34]. - The stock market is increasingly viewed as a primary asset class with significant mid-term growth potential, especially as real estate's role in economic growth diminishes [5][34]. Geopolitical and Economic Context - The ongoing geopolitical tensions, particularly between the US and China, are reshaping the investment landscape, with implications for market dynamics and corporate performance [8][39]. - The competition between the US and China is recognized as a critical geopolitical issue, influencing market sentiment and investment strategies [8][39]. Market Valuation and Structural Changes - The valuation framework of the A-share market is undergoing significant changes, with a notable divergence in performance between consumer stocks and technology sector stocks [40]. - The market's valuation adjustments may reflect a broader shift towards innovation-driven growth, necessitating a reevaluation of traditional investment strategies [40][43]. Investment Themes for 2026 - Key investment themes for 2026 include the continued focus on AI and technology innovation, resource commodities like gold, silver, and copper, and the potential for price increases in various sectors due to supply-demand dynamics [22][26][28]. - The performance of innovative pharmaceuticals is also highlighted, with expectations for continued growth driven by successful business development transactions and advancements in drug development [26][27].

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 28.36 million yuan, and the underlying index, the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Select 50 Index (HSSSHID), has risen nearly 3%, marking a strong performance with several constituent stocks like Kelaiying (06821) and Yifang Bio (688382) showing notable gains [1] Product Highlights - The innovative drug ETF Tianhong (517380) spans the markets of Shanghai, Hong Kong, and Shenzhen, selecting 50 leading innovative drug companies, with 40% from Hong Kong and 60% from A-shares, covering key areas such as biopharmaceuticals and chemical pharmaceuticals [1] Relevant Events - The new national medical insurance directory and the first commercial insurance innovative drug directory were implemented on January 1, 2026, adding 50 types of first-class innovative drugs and 19 types of commercial insurance drugs, establishing a "medical insurance + commercial insurance" payment loop. In 2025, China approved 76 innovative drugs, a significant increase of 58.3% from 48 in 2024, with over 80% being domestically produced, laying a foundation for sales growth in 2026 [1] Industry Trends - China's innovative drug licensing abroad has seen a breakthrough, with total transaction amounts reaching 135.655 billion USD by December 31, 2025, including upfront payments of 7 billion USD and 157 transactions, significantly surpassing the 51.9 billion USD and 94 transactions recorded in 2024 [2] - According to Zhongtai Securities, the pharmaceutical market is expected to continue benefiting from innovation-driven growth and industrial upgrades, with investment strategies for 2026 focusing on innovative drugs and their supply chains, demand recovery, and AI-related opportunities [2] Market Dynamics - The current innovative drug market differs from the 2019-2021 period, as the focus has shifted from narrative to actual execution, with transaction amounts reaching new highs, reflecting a transition in China's innovative capabilities from quantity to quality. Continuous policy support for innovative drugs, including the introduction of a commercial insurance directory, is expected to enhance payment options [3] - Companies with mature products successfully entering multinational corporations (MNCs) and those with strong platform advantages in cutting-edge technologies (such as ADC, small nucleic acids, and bispecific antibodies) are recommended for attention, along with potential collaboration opportunities [3]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market's innovative drug index is experiencing growth, indicating a positive trend in the pharmaceutical sector, particularly in innovative drugs [1] - As of 09:40, the Hong Kong Stock Connect innovative drug index rose by 1.59%, with individual stocks like Kangfang Biotech increasing over 3%, and others such as Kelun-Bio, CSPC Pharmaceutical, and Hansoh Pharmaceutical rising over 2% [1] - The report from Donghai Securities suggests that by 2026, China's pharmaceutical and biotechnology industry will enter a new era of innovative drugs, which will gradually dominate the sector, supported by the complementary relationship between medical insurance and commercial insurance [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF, managed by Harvest (520970), tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.71% of the total weight [2] - The management and custody fees for the Harvest innovative drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Core Viewpoint - The Hong Kong stock market's innovative drug sector has shown significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% and 36 out of 37 covered companies reporting gains, indicating a strong performance in the sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a rapid increase of over 3.6% [1] - 36 out of the 37 innovative drug companies covered by the ETF reported positive performance, with Syncona Health-B leading with a surge of over 13% [1] - Major player Kangfang Biologics saw an increase of nearly 5% [1] Group 2: Regulatory Approvals and Developments - Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" became the first domestically approved CTLA-4 inhibitor, filling a gap in the dual immune new adjuvant therapy field in China [1] - AstraZeneca and Daiichi Sankyo's TROP2 ADC "Dercutuzumab" received approval for breast cancer indications, further solidifying the advantages in the ADC sector [1] Group 3: Industry Trends and Projections - The innovative drug business development (BD) transactions are on the rise, with the total authorization amount for Chinese innovative drugs reaching $135.655 billion and 157 transactions recorded in 2025, both setting historical highs [1] - China's pipeline of new drugs now accounts for 30% of the global total, ranking second worldwide [1] - Analysts suggest that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation restructuring expected by 2026 [1][2] Group 4: Investment Strategies - Huafu Securities maintains that the long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance indicating good opportunities for innovative drugs and devices in 2026 [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: pure focus on innovative drugs, significant weight on leading companies, and better risk control [2] - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF (562050) and its associated fund (024986) are recommended, which focus on the top 50 A-share pharmaceutical companies and include a significant portion of traditional Chinese medicine [2][3]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has seen a resurgence, with the high-volatility Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% on January 7, 2023, and 36 out of 37 covered innovative drug companies showing positive performance [1][7]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) quickly surged by 3.61%, reaching a price of 0.545 [2][7]. - Among the covered companies, Tongyu Pharmaceutical-B soared over 13%, while the leading company, Kangfang Biopharmaceutical, increased nearly 5% [1][7]. Group 2: Industry Developments - Innovative drug business development (BD) transactions are continuing to grow, with the total amount of outbound licensing for Chinese innovative drugs expected to reach $135.655 billion by 2025, marking a historical high with 157 transactions [3][9]. - China's pipeline of new drugs currently accounts for 30% of the global total, ranking second worldwide [3][9]. - The biopharmaceutical industry is entering a critical phase of innovation realization and global layout, with a potential performance inflection point and valuation restructuring expected by 2026 [3][9]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated fund (025221) track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drugs, has a high concentration of leading companies (over 73% in the top ten), and has controlled risks by reducing the weight of less liquid stocks [3][9]. - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF in the market (562050) and its associated fund (024986) focus on the top 50 A-share pharmaceutical companies, with approximately 60% in innovative drugs and 25% in traditional Chinese medicine [4][10].

Core Viewpoint - The Shanghai Composite Index has broken through previous highs, confirming the onset of a spring market rally, with significant trading volume and a resurgence of market sentiment [1] Group 1: Market Overview - The Shanghai Composite Index reached a new high, indicating a new upward wave in the market, with trading volume exceeding 2.8 trillion [1] - The market is experiencing a spring rally, with a focus on the sustainability of hot sectors and increasing trading volume [1] Group 2: Future Market Outlook - The spring rally is expected to continue into January, driven by the resolution of global uncertainties and the easing of year-end funding tightness [1] - Key themes for the rally include technology growth narratives and rising raw material prices, primarily fueled by the AI industry investment boom [1] Group 3: Hot Sectors - In January, technology and raw material price increases are expected to dominate, with a focus on sectors like commercial aerospace, brain-computer interfaces, low-altitude economy, and semiconductors [2] - The rise in raw material prices is seen as a derivative of technology investments, with opportunities in small metals, energy metals, and new chemical materials [2] - Traditional high-dividend sectors are also noted for potential upside as the annual report season approaches [2] Group 4: Specific Trends and Opportunities - The trend of AI hardware remains strong, with a significant increase in token usage for major AI models, indicating a peak in AI applications by 2026 [2] - The domestic production of robots is expected to grow, expanding from humanoid robots to quadrupedal and functional robots, creating opportunities in sensors, controllers, and dexterous hands [2] - The trend towards semiconductor localization continues, with a focus on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue through 2026 [2] - The innovative drug sector is entering a recovery phase after four years of adjustment, with positive net profit growth expected to continue into 2026 [2]

Group 1 - The core viewpoint of the news highlights a significant rebound in the Hong Kong stock market's innovative drug sector, with the Hong Kong Stock Connect innovative drug ETF (520880) experiencing a notable increase of 2.85% and a trading volume exceeding 300 million yuan in just three days of the new year, reflecting a total gain of over 9% in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index [1] - The innovative drug sector has shown signs of reversal after a previous adjustment period, with a decline of over 24% from early September 2025 to December 31, 2025, indicating a potential opportunity for medium to long-term investment in core innovative drug assets [1] - The long-term logic of medical innovation remains unchanged, with the recent positive market performance signaling a good start for 2026, suggesting that innovative drugs and medical devices, as the most technology-driven segment, are likely to present favorable opportunities in the coming year [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated off-market fund (025221) are highlighted as key investment opportunities during the current low-entry window, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index offering three unique advantages: purity and comprehensiveness, significant weight of leading companies, and better risk control through forced de-weighting of less liquid stocks [2] - The index exclusively covers innovative drug R&D companies, ensuring a focused investment approach without including CXO companies, which enhances its appeal to investors seeking pure innovative drug exposure [2] - The top ten leading innovative drug companies account for over 73% of the index's weight, underscoring the strength of the innovative drug sector and providing a solid foundation for potential growth [2]

Market Overview - A-shares showed a positive trend with the Shanghai Composite Index up 0.22% to 4092.52, the Shenzhen Component Index up 0.46% to 14086.74, and the ChiNext Index up 0.52% to 3336.66 [1] - Hong Kong stocks experienced a decline, with the Hang Seng Index down 0.71% to 26520.16 and the Hang Seng Tech Index down 1.12% to 5760.21 [2][3] Bond Market - The bond market saw a continuous decline in government bond futures, with the 30-year contract down 0.13%, the 10-year contract down 0.04%, the 5-year contract down 0.04%, and the 2-year contract down 0.02% [3][4] Commodity Market - Domestic commodity futures experienced a broad increase, with coking coal rising over 5%, glass and silver rising over 4%, and other commodities like coke, stainless steel, and aluminum oxide rising over 2% [4][5] Innovation Drug Sector - The innovative drug sector showed active performance, with companies like Bibete reaching a 20% limit up, and others like Chengdu Xian Dao and Yinuo Si rising over 13% [6] - The total value of outbound licensing transactions in China's innovative drug industry is expected to exceed $130 billion by 2025, with 76 new drugs launched, both setting historical highs [6][7] Nickel and Rare Metals Sector - The nickel sector saw significant gains, with companies like Zhongwei Co. rising over 15% and GreenMe approaching a limit up [8][9] - The main nickel contract on the Shanghai Futures Exchange hit a limit up, while LME nickel prices rose over 10%, reaching $18,735 per ton, the highest since June 2024 [9] Storage Chip Sector - The storage chip sector opened strongly, with companies like Purun Co. hitting a 20% limit up and others like Hengsuo Co. and Jiangbolong rising over 10% [11][12] - The surge in the sector was influenced by significant gains in U.S. stocks, with SanDisk up over 27%, Western Digital up over 16%, and Micron Technology up over 10% [12]

Group 1: Electronic Industry - The electronic industry holds a weight of 33% in the Sci-Tech Innovation 200 index, with a positive outlook for 2026 driven by the dual forces of semiconductor self-sufficiency and AI innovation [1] - National policies are strongly supporting self-sufficiency in the electronic and semiconductor sectors, with the National Big Fund's third phase raising over 300 billion yuan, focusing on critical areas such as equipment and materials [1] - The continuous demand for AI computing power is a key driver, with domestic companies providing the necessary support for computing power, which is expected to benefit the electronic sector on the Sci-Tech Innovation Board [1] Group 2: Pharmaceutical Industry - The pharmaceutical industry accounts for approximately 20% of the index, with a core viewpoint that the value of Chinese innovative drugs is gaining international recognition, marking a critical turning point [2] - The Chinese pharmaceutical industry has undergone significant transformation over the past decade, with a full-chain support policy for innovative drugs set to elevate their development to a national strategic level [2] - The number of self-researched FIC drugs by Chinese companies has increased from 9 in 2015 to 120 in 2024, representing 31% of the global pipeline, second only to the United States [2][6] Group 3: Machinery and Equipment Industry - The machinery and equipment sector represents 12% of the index, benefiting from strong policy support and emerging growth trends, particularly in high-end manufacturing [6] - The "14th Five-Year Plan" emphasizes original innovation and key technology breakthroughs in industries such as integrated circuits and high-end instruments, which will drive growth in the machinery sector [6] - The commercial progress of robotics is expected to reach a turning point by 2026, with domestic supply chain changes and industrialization pace accelerating [7] Group 4: Investment Opportunities - The Guotai Sci-Tech 200 ETF (subscription code: 589223) fills the gap for small-cap allocations in the Sci-Tech Innovation Board, offering high growth potential and low entry barriers for investors [7]